Pilot Study of a Metabolic Nutritional Therapy for the Management of Primary Brain Tumors
Conditions: official terms
Brain Neoplasms
Conditions: Keywords
ketogenic diet, brain tumors
Study Type
Study Phase
Study Design
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Name: Energy restricted Ketogenic Diet (ERKD) (Metabolic Nutritional Therapy)
Type: Other
Overall Status
This study will look at the effects, good and/or bad, of treating primary brain cancers with diet therapy using an energy restricted ketogenic diet (ERKD) that uses food. An energy restricted ketogenic diet is a diet designed to keep blood sugars in the low range of normal while at the same time increasing the blood concentration of metabolic break down products called ketones. This diet is currently used to treat children with uncontrollable seizures. This diet is well tolerated by the children with minimal side effects reported after using the diet for years.

- The main purpose of this study is to find out whether or not the energy restricted ketogenic diet will help patients with primary brain cancer by either decreasing the size of the cancer or by keeping the cancer from growing.

- Another reason for doing this study is to learn about the side effects associated with the energy restricted ketogenic diet in patients with primary brain cancer.
Detailed Description
Summary: The current standard of care for glioblastoma multiforme (GBM), the most common primary brain tumor in adults, includes surgical resection, radiation and chemotherapy. Survival rarely exceeds 18 months. The investigators propose to test the hypothesis that brain tumor cells are unable to utilize ketones as a source of energy when deprived of glucose, due to mitochondrial dysfunction, whereas normal glia and neurons can survive this metabolic stress. A nutritionally adequate but energy restricted, ketogenic diet (ERKD) to deprive brain tumors of energy and resulting in death of glioma cells is promising. ERKD-based therapy to manage brain cancer is both biologically plausible and supported by data in animal models. A multidisciplinary team of oncologists, registered dietitians, and physiologists will implement an ERKD therapy in newly diagnosed GBM subjects. After initial maximal tumor excision, ERKD therapy will be initiated for subjects during a one week inpatient admission to Sparrow Hospital or as a local outpatient and supervised by registered dietitians experienced in implementing this therapy.The ERKD will continue as adjunctive therapy along with radiation therapy and standard of care chemotherapy. The supervised ERKD will continue for an additional 6 weeks after completion of radiation therapy along with the standard of care chemotherapy. The objective of this trial is to determine whether the ERKD decreases tumor size or results in no recurrence in individuals with GBM as measured by serial MRI imaging. Enzymes and signaling pathways that regulate metabolism and cell growth will be assessed in initial and post-ERKD tumors using standard biochemical approaches.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: 90 Years
Minimum Age: 18 Years
Gender: Both
Criteria: - Inclusion Criteria:

- Adult subjects over age 18 with biopsy proven GBM diagnosis

- Measurable disease after standard therapies

- Eastern Cancer Oncology Group performance status < or =2; and

- Life expectancy >3 months.

Exclusion Criteria:

- Diagnosis of diabetes mellitus that is being treated by medication

- Concomitant use of glucocorticosteroids

- Cholecystectomy within 1 year prior to study entry

- Inability to adhere to or tolerate dietary protocol

- Active malignancy other than primary brain tumor requiring therapy

- Participation in an investigational study within 2 weeks prior to study entry; Major co-morbidities such as liver, kidney or heart failure that in the judgment of the investigators would disqualify the subject from the trial

- Pregnancy

- Inability to give informed consent
Michigan State University/Sparrow Hospital
E. Lansing, Michigan, United States
Status: Recruiting
Contact: Ken A. Schwartz, MD - 517-353-4811 - ken.schwartz@hc.msu.edu
Start Date
April 2012
Completion Date
November 2015
Michigan State University
Michigan State University
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page